Pieris Pharmaceuticals Announces First Patient Dosed in SELVA Phase 3 Trial

TipRanksNov 7 08:53 ET

Express News | Palvella Therapeutics Announces First Patient Dosed in Selva Phase 3 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations

ReutersNov 7 08:30 ET

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN Rapamycin) for the Treatment of Microcystic Lymphatic Malformations

GlobeNewswireNov 7 08:30 ET

Express News | Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

ReutersOct 17 07:30 ET

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

GlobeNewswireOct 15 07:30 ET

Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

BenzingaOct 3 07:42 ET